Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065192 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
A Phase 1 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03065192 is a Phase 1 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 16 participants.
The verdict
NCT03065192, a Phase 1 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.
Interventions
- DRUG VY-AADC01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2021-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03065192
The ClinicalTrials.gov registry entry for NCT03065192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VY-AADC01 is the first listed.
NCT03065192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03065192 about?
NCT03065192 is a clinical study titled "Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease". Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.
What is the current status of trial NCT03065192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-05-11. Estimated completion is 2021-08-10.
What interventions are being tested in trial NCT03065192?
The interventions under investigation include: VY-AADC01 (DRUG).
Who is sponsoring clinical trial NCT03065192?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.